Ultragenyx Pharmaceutical Inc. (RARE)

Market Cap	2.22B
Revenue (ttm)	630.60M
Net Income (ttm)	-579.83M
Shares Out	96.30M
EPS (ttm)	-5.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,675,794
Open	22.50
Previous Close	22.78
Day's Range	21.90 - 23.06
52-Week Range	18.41 - 46.50
Beta	0.16
Analysts	Strong Buy
Price Target	79.11 (+243.96%)
Earnings Date	Feb 12, 2026

About RARE

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2014
• Employees: 1,294
• Stock Exchange: NASDAQ
• Ticker Symbol: RARE
• Website: https://www.ultragenyx.com

Financial Performance

In 2024, Ultragenyx Pharmaceutical's revenue was $560.23 million, an increase of 29.01% compared to the previous year's $434.25 million. Losses were -$569.18 million, -6.17% less than in 2023.

Analyst Summary

According to 19 analysts, the average rating for RARE stock is "Strong Buy." The 12-month stock price target is $79.11, which is an increase of 243.96% from the latest price.

Price Target

$79.11

(243.96% upside)

Analyst Consensus: Strong Buy